Scilex (SCLX) Competitors $0.97 +0.01 (+1.04%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SCLX vs. MKTW, OCS, IMNM, STOK, TRML, ORIC, YMAB, TRDA, ABVX, and HUMAShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include MarketWise (MKTW), Oculis (OCS), Immunome (IMNM), Stoke Therapeutics (STOK), Tourmaline Bio (TRML), ORIC Pharmaceuticals (ORIC), Y-mAbs Therapeutics (YMAB), Entrada Therapeutics (TRDA), ABIVAX Société Anonyme (ABVX), and Humacyte (HUMA). Scilex vs. MarketWise Oculis Immunome Stoke Therapeutics Tourmaline Bio ORIC Pharmaceuticals Y-mAbs Therapeutics Entrada Therapeutics ABIVAX Société Anonyme Humacyte MarketWise (NASDAQ:MKTW) and Scilex (NASDAQ:SCLX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Which has better earnings and valuation, MKTW or SCLX? MarketWise has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than MarketWise, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarketWise$448.18M0.42$1.78M$0.087.41Scilex$46.74M3.99-$114.33M-$1.43-0.68 Which has more risk and volatility, MKTW or SCLX? MarketWise has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Do analysts rate MKTW or SCLX? MarketWise currently has a consensus target price of $2.50, suggesting a potential upside of 321.51%. Scilex has a consensus target price of $11.33, suggesting a potential upside of 1,066.70%. Given Scilex's stronger consensus rating and higher possible upside, analysts clearly believe Scilex is more favorable than MarketWise.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MarketWise 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Scilex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor MKTW or SCLX? In the previous week, Scilex had 6 more articles in the media than MarketWise. MarketBeat recorded 10 mentions for Scilex and 4 mentions for MarketWise. Scilex's average media sentiment score of 0.85 beat MarketWise's score of 0.47 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MarketWise 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in MKTW or SCLX? 23.0% of MarketWise shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 28.6% of MarketWise shares are held by company insiders. Comparatively, 8.7% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is MKTW or SCLX more profitable? MarketWise has a net margin of 0.80% compared to Scilex's net margin of -233.88%. Scilex's return on equity of 0.00% beat MarketWise's return on equity.Company Net Margins Return on Equity Return on Assets MarketWise0.80% -1.30% 0.91% Scilex -233.88%N/A -111.82% Does the MarketBeat Community believe in MKTW or SCLX? MarketWise received 16 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 65.00% of users gave MarketWise an outperform vote. CompanyUnderperformOutperformMarketWiseOutperform Votes2665.00% Underperform Votes1435.00% ScilexOutperform Votes10100.00% Underperform VotesNo Votes SummaryScilex beats MarketWise on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$186.31M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.6812.18115.5615.18Price / Sales3.99332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book-0.884.024.665.02Net Income-$114.33M-$42.25M$119.06M$225.46M7 Day Performance12.77%8.06%0.80%0.37%1 Month Performance10.81%8.71%5.65%3.57%1 Year Performance-47.49%32.10%36.76%29.44% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex2.8666 of 5 stars$0.97+1.0%$11.33+1,066.7%-46.3%$186.31M$46.74M-0.6880MKTWMarketWise4.0126 of 5 stars$0.59+1.7%$2.50+321.5%-73.3%$187.40M$448.18M7.41578Upcoming EarningsGap UpOCSOculis1.9668 of 5 stars$17.88+4.1%$29.20+63.3%+96.5%$724.14M$980,000.00-9.312Gap DownHigh Trading VolumeIMNMImmunome2.4973 of 5 stars$11.59+1.0%$29.00+150.2%+35.2%$695.98M$14.02M-1.5140Short Interest ↓Gap UpSTOKStoke Therapeutics3.835 of 5 stars$12.86+4.0%$20.83+62.0%+215.2%$677.08M$8.78M-5.90100Upcoming EarningsPositive NewsTRMLTourmaline Bio3.4393 of 5 stars$26.30+3.1%$64.67+145.9%+52.7%$674.33MN/A-7.1544ORICORIC Pharmaceuticals4.2103 of 5 stars$9.41+0.3%$18.29+94.3%+43.2%$663.78MN/A-5.3880Upcoming EarningsAnalyst ForecastNews CoverageYMABY-mAbs Therapeutics3.3056 of 5 stars$14.74+1.6%$21.14+43.4%+163.2%$656.96M$84.82M-26.32150Upcoming EarningsNews CoveragePositive NewsTRDAEntrada Therapeutics2.4135 of 5 stars$17.60+2.7%$21.50+22.2%+13.5%$654.72M$129.01M5.95110Upcoming EarningsPositive NewsABVXABIVAX Société Anonyme3.3503 of 5 stars$10.27-0.5%$36.50+255.4%+5.2%$649.99MN/A0.0061Positive NewsHigh Trading VolumeHUMAHumacyte3.1748 of 5 stars$5.39+6.7%$10.00+85.5%+170.9%$643.30M$1.57M-4.28150News Coverage Related Companies and Tools Related Companies MKTW Alternatives OCS Alternatives IMNM Alternatives STOK Alternatives TRML Alternatives ORIC Alternatives YMAB Alternatives TRDA Alternatives ABVX Alternatives HUMA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCLX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.